{"id":"new-regimen-bdqcfzlzd-xy","safety":{"commonSideEffects":[{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"QT prolongation"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Photosensitivity (clofazimine)"}]},"_chembl":{"chemblId":"CHEMBL5283859","moleculeType":null,"molecularWeight":"347.92"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The regimen combines bedaquiline (ATP synthase inhibitor), clofazimine (redox-active agent), and linezolid (protein synthesis inhibitor) with two unspecified agents (XY) to provide synergistic activity against multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis. This multi-drug approach aims to overcome resistance mechanisms and improve treatment outcomes in difficult-to-treat TB cases.","oneSentence":"This is a combination regimen of bedaquiline, clofazimine, linezolid, and two additional agents (XY) designed to treat drug-resistant tuberculosis by targeting multiple mycobacterial pathways simultaneously.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:57:02.093Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Drug-resistant tuberculosis (MDR-TB and XDR-TB)"}]},"trialDetails":[{"nctId":"NCT05494957","phase":"PHASE4","title":"Clinical Study of New Intensive Treatment Regimen for Severe Nontuberculous Mycobacterial Pulmonary Disease","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2022-08-05","conditions":"Nontuberculous Mycobacterial Lung Disease","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["New regimen for NTM-PD(BdqCfzLzd+XY)"],"phase":"marketed","status":"active","brandName":"New regimen(BdqCfzLzd+XY)","genericName":"New regimen(BdqCfzLzd+XY)","companyName":"Shanghai Pulmonary Hospital, Shanghai, China","companyId":"shanghai-pulmonary-hospital-shanghai-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination regimen of bedaquiline, clofazimine, linezolid, and two additional agents (XY) designed to treat drug-resistant tuberculosis by targeting multiple mycobacterial pathways simultaneously. Used for Drug-resistant tuberculosis (MDR-TB and XDR-TB).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}